Bevacizumab — Dosing in CKD & Dialysis

Bevacizumab (Antineoplastic): renal dosing adjustments, dialyzability (Negligible (dialyser extraction 0% and hemodialysis clearance 0 mL/min in one HD patient; Garnier-Viougeat 2007, PMID 17093010)), and renal-relevant safety risk for CKD and dialysis patients. Educational reference for nephrology

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.